NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.60 USD
+0.02 (0.78%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $2.65 +0.05 (1.92%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRXP 2.60 +0.02(0.78%)
Will NRXP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NRXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRXP
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
NRXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for April 4th
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
Other News for NRXP
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
NRx Pharmaceuticals to proceed with two new NDAs in 2024
NRX Pharmaceuticals Faces Agreement Termination, Eyes Accelerated Approval
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors